1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol,a novel subtype selective inhibitor of the mouse type II GABA-transporter |
| |
Authors: | Christian Thomsen Per Olaf S?rensen Jan Egebjerg |
| |
Affiliation: | Novo Nordisk A/S, Departments of Molecular Pharmacology, DK-2760 Måløv, Denmark;*Medicinal Chemistry II, Novo Nordisk Park, DK-2760 Måløv, Denmark;†Medicinal Chemistry II,Molecular Genetics, Novo Nordisk Park, DK-2760 Måløv, Denmark |
| |
Abstract: | The selectivity of new derivatives of the γ-aminobutyric acid (GABA)-uptake inhibitor, tiagabine was characterized at the four cloned mouse GABA transporters (mGAT1 through mGAT4) by measuring [3H]-GABA uptake into stably transfected baby hamster kidney cells. While tiagabine is a highly selective inhibitor of mGAT1 (Ki=0.11±0.02 μM), these derivatives exhibited low potencies at mGAT1 but differential activities at mGAT2, mGAT3 and mGAT4. In particular, 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol (NNC 05-2090) was a potent inhibitor of mGAT2 (Ki=1.4±0.3 μM) showing at least 10 fold selectivity over mGAT1, mGAT3 and mGAT4. NNC 05-2090 is the first subtype selective inhibitor of mGAT2 and may represent a novel useful tool for investigating the physiological roles of GAT2 in the brain and periphery. |
| |
Keywords: | γ -Aminobutyric acid (GABA) uptake, lipophilic GABA uptake inhibitor, BGT-1, tiagabine, 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol (NNC 05-2090) |
|
|